Cargando…
Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS
Introduction: Malignant pleural mesothelioma (MPM) is a malignancy with a very poor prognosis for which new treatment options are urgently needed. We have previously shown that dendritic cell (DC) immunotherapy provides a clinically feasible treatment option. In the current study, we set out to asse...
Autores principales: | de Goeje, Pauline L., Klaver, Yarne, Kaijen-Lambers, Margaretha E. H., Langerak, Anton W., Vroman, Heleen, Kunert, André, Lamers, Cor H. J., Aerts, Joachim G. J. V., Debets, Reno, Hendriks, Rudi W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137618/ https://www.ncbi.nlm.nih.gov/pubmed/30245692 http://dx.doi.org/10.3389/fimmu.2018.02034 |
Ejemplares similares
-
T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients
por: Klaver, Yarne, et al.
Publicado: (2016) -
Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy
por: Noordam, Lisanne, et al.
Publicado: (2018) -
Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes
por: Klaver, Yarne, et al.
Publicado: (2020) -
Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma
por: Mahaweni, Niken M., et al.
Publicado: (2013) -
Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma
por: Minnema-Luiting, Jorien, et al.
Publicado: (2018)